839 related articles for article (PubMed ID: 26076081)
1. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.
Bai F; Wang C; Lu Q; Zhao M; Ban FQ; Yu DH; Guan YY; Luan X; Liu YR; Chen HZ; Fang C
Biomaterials; 2013 Aug; 34(26):6163-74. PubMed ID: 23706689
[TBL] [Abstract][Full Text] [Related]
3. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
4. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature.
Yu DH; Lu Q; Xie J; Fang C; Chen HZ
Biomaterials; 2010 Mar; 31(8):2278-92. PubMed ID: 20053444
[TBL] [Abstract][Full Text] [Related]
5. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
6. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
7. Mammary-Derived Growth Inhibitor Targeting Peptide-Modified PEG-PLA Nanoparticles for Enhanced Targeted Glioblastoma Therapy.
Feng X; Gao X; Kang T; Jiang D; Yao J; Jing Y; Song Q; Jiang X; Liang J; Chen J
Bioconjug Chem; 2015 Aug; 26(8):1850-61. PubMed ID: 26222392
[TBL] [Abstract][Full Text] [Related]
8. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
9. Suppression of colorectal cancer subcutaneous xenograft and experimental lung metastasis using nanoparticle-mediated drug delivery to tumor neovasculature.
Wang C; Zhao M; Liu YR; Luan X; Guan YY; Lu Q; Yu DH; Bai F; Chen HZ; Fang C
Biomaterials; 2014 Jan; 35(4):1215-26. PubMed ID: 24231414
[TBL] [Abstract][Full Text] [Related]
10. CGKRK-modified nanoparticles for dual-targeting drug delivery to tumor cells and angiogenic blood vessels.
Hu Q; Gao X; Kang T; Feng X; Jiang D; Tu Y; Song Q; Yao L; Jiang X; Chen H; Chen J
Biomaterials; 2013 Dec; 34(37):9496-508. PubMed ID: 24054848
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance.
Jin X; Mo R; Ding Y; Zheng W; Zhang C
Mol Pharm; 2014 Jan; 11(1):145-57. PubMed ID: 24261922
[TBL] [Abstract][Full Text] [Related]
12. PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy.
Gu G; Hu Q; Feng X; Gao X; Menglin J; Kang T; Jiang D; Song Q; Chen H; Chen J
Biomaterials; 2014 Sep; 35(28):8215-26. PubMed ID: 24974009
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Antiglioblastoma Efficacy of Neovasculature and Glioma Cells Dual Targeted Nanoparticles.
Lv L; Jiang Y; Liu X; Wang B; Lv W; Zhao Y; Shi H; Hu Q; Xin H; Xu Q; Gu Z
Mol Pharm; 2016 Oct; 13(10):3506-3517. PubMed ID: 27636161
[TBL] [Abstract][Full Text] [Related]
14. Multi-targeting Peptide-Functionalized Nanoparticles Recognized Vasculogenic Mimicry, Tumor Neovasculature, and Glioma Cells for Enhanced Anti-glioma Therapy.
Feng X; Yao J; Gao X; Jing Y; Kang T; Jiang D; Jiang T; Feng J; Zhu Q; Jiang X; Chen J
ACS Appl Mater Interfaces; 2015 Dec; 7(50):27885-99. PubMed ID: 26619329
[TBL] [Abstract][Full Text] [Related]
15. A novel approach to overcome multidrug resistance: utilization of P-gp mediated efflux of paclitaxel to attack neighboring vascular endothelial cells in tumors.
Yoshizawa Y; Ogawara K; Kimura T; Higaki K
Eur J Pharm Sci; 2014 Oct; 62():274-80. PubMed ID: 24956463
[TBL] [Abstract][Full Text] [Related]
16. Co-encapsulation of paclitaxel and baicalein in nanoemulsions to overcome multidrug resistance via oxidative stress augmentation and P-glycoprotein inhibition.
Meng L; Xia X; Yang Y; Ye J; Dong W; Ma P; Jin Y; Liu Y
Int J Pharm; 2016 Nov; 513(1-2):8-16. PubMed ID: 27596118
[TBL] [Abstract][Full Text] [Related]
17. 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.
Baek JS; Cho CW
J Pharm Pharmacol; 2013 Jan; 65(1):72-8. PubMed ID: 23215690
[TBL] [Abstract][Full Text] [Related]
18. A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity.
Zhou H; Lv S; Zhang D; Deng M; Zhang X; Tang Z; Chen X
Acta Biomater; 2018 Jun; 73():388-399. PubMed ID: 29694920
[TBL] [Abstract][Full Text] [Related]
19. Neovasculature and circulating tumor cells dual-targeting nanoparticles for the treatment of the highly-invasive breast cancer.
Yao J; Feng J; Gao X; Wei D; Kang T; Zhu Q; Jiang T; Wei X; Chen J
Biomaterials; 2017 Jan; 113():1-17. PubMed ID: 27794222
[TBL] [Abstract][Full Text] [Related]
20. Dual drug-loaded nano-platform for targeted cancer therapy: toward clinical therapeutic efficacy of multifunctionality.
Ma Z; Li N; Zhang B; Hui Y; Zhang Y; Lu P; Pi J; Liu Z
J Nanobiotechnology; 2020 Sep; 18(1):123. PubMed ID: 32887626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
